NORTHFIELD, Ill.--(BUSINESS WIRE)--The College of American Pathologists (CAP) in collaboration with the International Association for the Study of Lung Cancer (IASLC), Pulmonary Pathology Society (PPS ...
Two viewpoint articles published in JAMA Oncology provide opposing opinions on the benefit of testing for programmed death-ligand 1 (PD-L1) expression in patients with non-small-cell lung cancer ...
GUILDFORD, UK / ACCESSWIRE / November 9, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in ...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today announced it has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to guide options for the first-line ...
BURLINGTON, N.C.--(BUSINESS WIRE)--Laboratory Corporation of America ® Holdings (LabCorp ®) (NYSE: LH) today announced the nationwide availability of a new FDA-approved diagnostic test for PD-L1 ...
Trastuzumab-based regimens were the primary treatment for older adults with advanced HER2-positive gastric cancer before immunotherapy became standard. The study highlights substantial economic ...
Jonathan Thompson, MD, MS, emphasized that comprehensive biomarker testing with next-generation sequencing and PD-L1 analysis—implemented as reflex testing at biopsy—is essential to guide precision ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback